The core activity of AdRegeneer AG is the development of regenerative medicines for the nervous system, particularly for the treatment of multiple sclerosis and spinal cord injuries.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered3
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of regenerative nervous system therapies
Development of regenerative therapies for multiple sclerosis, neurodegenerative diseases and traumatic injuries; epigenetic drugs, gene therapies, remyelination and axonal regrowth.
Preclinical drug and target development
Preclinical development of drug candidates and targets, with six preclinical programmes validated in animal models and cell-based assays; focus on HDAC2 and myelination.
Clinical trials for transdermal therapies and remyelination
Phase I and Phase II clinical trials for transdermal patches and a remyelination-focused formulation for multiple sclerosis.
Comparisons
AdRegeneer AG in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank AdRegeneer AG by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once AdRegeneer AG has claimed this profile, we'll publish editorial articles and case studies here together.